Press Release Details

G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022

January 4, 2022 at 9:15 AM EST

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January.

  • G1’s Chief Executive Officer Jack Bailey and Chief Medical Officer Raj Malik, M.D. will participate in a fireside chat during the H.C. Wainwright BioConnect 2022 conference. The webcast of the fireside chat will become available at 7:00 AM EST on January 10, 2022.
  • On January 12, 2022, at 1:30 PM EST, Mr. Bailey will provide a corporate presentation during the 40th Annual J.P. Morgan Healthcare Conference.

The webcast of both events will be accessible on the Events & Presentations page of

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter @G1Therapeutics.

Will Roberts
Vice President, Investor Relations & Corporate Communications

Primary Logo

Source: G1 Therapeutics